Tigecycline therapy for multidrug-resistant bacteria: is it the right choice for pediatric patients
Open Access
- 28 July 2025
- journal article
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (07) , 1046-1054
Abstract
Introduction: The incidence of infections caused by multidrug-resistant pathogens is increasing worldwide, resulting in significant morbidity and mortality. Tigecycline has become a good option because it has a broad spectrum of antibacterial activity. This study aimed to reveal the clinical, microbiological, and laboratory outcomes of hospitalized children treated with tigecycline. Methodology: We retrospectively collected the medical records of the hospitalized pediatric patients treated with tigecycline from April 1, 2018, to Apr 30, 2023, at Ege University Children's Hospital. Demographic features and clinical and laboratory findings were evaluated to determine the efficacy and safety of tigecycline therapy. Results: Sixty-seven patients (65.7% male) with a median age of 6 years (2.5 months-17.5 years) were included. There was an underlying condition in 83.5% of the patients, and 55.2% were immunosuppressed. The most common infections were; lower respiratory tract infections (29.8%), intra-abdominal infections (20.9%), bloodstream infections (17.9%), and soft tissue infections (13.4%), respectively. Acinetobacter spp. (28.4%) was the most isolated microorganism, followed by Klebsiella spp. (19.4%) and Enterococcus spp. (14.9%). Tigecycline was used as a targeted treatment in 76.1% of the patients and was often used as a combination therapy (80.6%) with a median duration of 12 days (range, 2-60 days). Clinical response was achieved in 65.6% of patients, microbiologic response in 62.6%, and treatment failure in 34.3%. No major adverse events were noted during the therapy. Conclusions: Tigecycline, which was mostly preferred in combination therapy, had high clinical response and microbiologic eradication rates, but these rates varied according to infection sites and microorganism species.Keywords
This publication has 22 references indexed in Scilit:
- Tigecycline therapy in pediatric patients with multidrug resistant bacteremiaEnfermedades Infecciosas y Microbiología Clínica, 2020
- Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgeryInternational Journal of Infectious Diseases, 2018
- Preliminary experience with tigecycline treatment for severe infection in childrenEuropean Journal of Pediatrics, 2018
- Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremiaInternational Journal of Infectious Diseases, 2017
- Use of tigecycline in pediatric clinical practiceExpert Review of Anti-infective Therapy, 2017
- Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a childJournal of Microbiology, Immunology and Infection, 2016
- Pharmacokinetics and Safety Profile of Tigecycline in Children Aged 8 to 11 Years With Selected Serious Infections: A Multicenter, Open-Label, Ascending-Dose StudyClinical Therapeutics, 2012
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin‐Structure Infections: Results of 2 Double‐Blind Phase 3 Comparison Studies with Vancomycin‐AztreonamClinical Infectious Diseases, 2005
- Long-term Survival and Function After Suspected Gram-negative SepsisJAMA, 1995